LEADER 01525nam  2200373 a 450 
001 9910701500803321
005 20120314080845.0
035   $a(CKB)5470000002418065
035   $a(OCoLC)780058778
035   $a(EXLCZ)995470000002418065
100   $a20120314d2011      ua             0
101 0 $aspa
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aInformacio?n sobre la buprenorfina para el tratamiento de la adiccio?n a los opia?ceos$b[electronic resource]
210  1$a[Rockville, MD] :$cU.S. Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment,$d2011.
215   $a1 online resource (20 unnumbered pages) $cillustrations
225 1 $aPublicacio?n del HHS ;$vno. (SMA) 10-4442Spanish
300   $aTitle from title screen (viewed on Mar. 14, 2012).
300   $a"Adaptado por JBS International, Inc., bajo el Contrato No. 270-09-0307"--P. [20].
606   $aOpioid abuse$xTreatment$zUnited States
606   $aBuprenorphine$xTherapeutic use
615  0$aOpioid abuse$xTreatment
615  0$aBuprenorphine$xTherapeutic use.
712 02$aJBS International (Firm)
712 02$aCenter for Substance Abuse Treatment (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910701500803321
996   $aInformacio?n sobre la buprenorfina para el tratamiento de la adiccio?n a los opia?ceos$93483275
997   $aUNINA